Business Wire17d
Imvax Announces Completion of $29 Million Financing and Confirms Timing for Topline Results of Phase 2b Trial of IGV-001 in Newly Diagnosed Glioblastoma
IGV-001 is derived from Imvax’s proprietary Goldspire® immuno-oncology platform, which is designed to use a patient’s own tumor cells to induce a broad and durable immune response against tumors.
Nasdaq26d
Government Contract Update: $54M payment to GINKGO BIOWORKS, INC.
We have seen $122,757,178 of award payments to $DNA over the last year. $DNA insiders have traded $DNA stock on the open market 12 times in the past 6 months. Of ...